多西紫杉醇、吉西他滨及培美曲塞二钠与顺铂联用化疗治疗晚期非小细胞肺癌疗效对比分析被引量：4

在线阅读下载PDF

导出

摘要选取我院近期收治晚期非小细胞肺癌患者60例,采用随机数字表法分为A组、B组和C组各20例。分别在顺铂基础上分别加用多西紫杉醇、吉西他滨及培美曲塞二钠治疗。比较三组患者临床疗效,治疗前后卡氏评分及药物不良反应发生情况等。结果 C组患者临床疗效显著高于A、B组,差异有统计学意义(P<0.05);三组患者治疗后卡氏评分均显著高于治疗前,差异有统计学意义(P<0.05);C组患者治疗后卡氏评分均显著高于A、B组,差异有统计学意义(P<0.05);同时C组患者消化道反应和骨髓抑制反应III-IV级发生率均显著低于A、B组,差异有统计学意义(P<0.05)。相较于多西紫杉醇和吉西他滨,培美曲塞二钠与顺铂联用化疗治疗晚期非小细胞肺癌可有效控制病情进展,改善生活质量,并有助于降低药物不良反应发生风险。

作者何学军姜勇王露崔林

机构地区泰州市第二人民医院肿瘤科

出处《现代诊断与治疗》 CAS 2015年第22期5148-5150,共3页 Modern Diagnosis and Treatment

关键词多西紫杉醇吉西他滨培美曲塞二钠顺铂非小细胞肺癌

分类号 R734.2 [医药卫生—肿瘤]

引文网络
相关文献

参考文献10

1孙燕,石远凯.临床肿瘤内科手册[M].北京:人民卫生社出版.2007.152.
2单彬彬,张全卯.晚期非小细胞肺癌表皮生长因子受体-酪氨酸激酶抑制剂二线治疗获得性耐药后培美曲塞化疗的疗效观察[J].肿瘤研究与临床,2013,25(10):702-704. 被引量：5
3张芳,殷文点,廉海容,蔡礼鸣.培美曲塞联合顺铂一线治疗晚期非小细胞肺癌的临床疗效观察[J].中华临床医师杂志（电子版）,2013,7(6):193-194. 被引量：9
4Liao ZX,Komaki RR,Thames HD,et a1.Influence of technologic advaneed on outcomes in patiens with unreseetable locally advanced non-small-cell lung cancer receiving concomitant ehemoradiotherapy[J].Int J Radiat Oncol Biol Phys,2010,76(2):775-781.
5孟丽娟,王峻,刘福银,樊卫飞,杨民,蒲骁麟.老年晚期非小细胞肺癌单药二线培美曲塞或多西他赛化疗的临床观察[J].实用老年医学,2010,24(1):66-68. 被引量：36
6王静,李峻岭,石远凯,张湘茹,王燕,郝学志,王彬,许建萍.吉西他滨联合顺铂在非小细胞肺癌辅助化疗中的应用[J].中国全科医学,2012,15(9):987-989. 被引量：60
7Water SE,Dingle B,Rodriguez G,et a1.Analysis of a novel protocol of combined induction chemotherapy and concurrent chemoradiation with vinblastine,cisplatin,and radiation therapy[J].Clin Lung Cancer,2010,11(3):243-250.
8张燕,王哲海.培美曲塞联合顺铂一线治疗晚期非小细胞肺癌临床观察[J].山东医药,2011,51(1):52-53. 被引量：41
9黄岩,刘云鹏,周建英,徐农,李宝兰,伍钢,方健,李凯,刘晓睛,刘巍,卢铀,王孟昭,刘文超,梁后杰,张沂平,黄诚,王顺金,王雅杰,于世英,常建华,王哲海,胡志皇,张力.培美曲塞联合顺铂对比吉西他滨联合顺铂一线治疗晚期非鳞非小细胞肺癌的随机、对照、多中心临床研究[J].中国肺癌杂志,2012,15(10):576-582. 被引量：38
10彭艳芝,张国栋.重组人血管内皮抑制素联合培美曲塞和顺铂治疗晚期非小细胞肺癌的临床观察[J].中华全科医师杂志,2013,12(4):298-299. 被引量：11

二级参考文献54

1周彩存,钟文昭.吉西他滨联合铂类与其他含铂方案治疗晚期非小细胞肺癌的疗效比较:关于生存结果的荟萃分析[J].循证医学,2005,5(3):143-146. 被引量：70
2王金万,孙燕,刘永煜,于起涛,张沂平,李凯,朱允中,周清华,侯梅,管忠震,李维廉,庄武,王东林,梁后杰,秦凤展,卢辉山,刘晓晴,孙红,张燕军,王杰军,罗素霞,杨瑞合,涂远荣,王秀问,宋恕平,周静敏,游丽芬,王竞,姚晨.重组人血管内皮抑素联合NP方案治疗晚期NSCLC随机、双盲、对照、多中心Ⅲ期临床研究[J].中国肺癌杂志,2005,8(4):283-290. 被引量：628
3虞永峰,庄兰妹,陆舜.抗肿瘤血管生成:肺癌治疗新希望——2006年ASCO新进展[J].肿瘤,2006,26(7):592-595. 被引量：9
4Gridelli C, Perrone F, Monfardini S. Lung cancer in the elderly[ J]. Eur J Cancer, 1997,33 (14) :2313-2314.
5Han K, Cao W, Che J, et al. First line chemotherapy with weekly docetaxel and cisplatin in elderly patients with advanced non-small cell lung cancer: a multicenter phase II study[J]. J Thorac Oncol, 2009, 4(4) :512-517.
6Tibaldi C, Vasile E, Antonuzzo A, et al. First line chemotherapy with planned sequential administration of gemcitabine followed by docetaxel in elderly advanced non-small-cell lung cancer patients : a multicenter phase II study [ J ]. Br J Cancer, 2008,98 ( 3 ) :558-563.
7Giorgio CG, Pappalardo A, Russo A, et al. A phase II study of carboplatin and paclitaxel as first line chemotherapy in elderly patients with advanced non-small cell lung cancer (NSCLC) [ J ]. Lung Cancer, 2006, 51 ( 3 ) :357-362.
8Pujol JL, Paul S, Chouaki N, et al. Survival without common toxicity criteria grade 3/4 toxicity for pemetrexed compared with docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC) : a risk-benefit analysis[J]. J Thorac Oncol, 2007, 2(5) :397-401.
9Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase Ⅲ trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy[J]. J Clin Oncol, 2004, 22(9) :1589-1597,.
10Kulkarni PM, Chen R, Anand T, et al. Efficacy and safety of pemetrexed in elderly cancer patients: results of an integrated analysis [ J ]. Crit Rev Oncol Hematol, 2008, 67 (1): 64-70.